PCSK9(His)-LDLR Binding Assay Kit
The PCSK9(His)-LDLR Binding Assay Kit is an ELISA-type 96-well format assay designed for screening and profiling purposes. Moreover, two pre-formulated assay buffers are supplied to validate PCSK9-LDLR binding affinity in either neutral or acidic binding conditions. The assay takes advantage of the high sensitivity of detection of His-tag PCSK9 by Anti-His HRP-antibody. First, the LDLR ectodomain is coated on a 96-well plate. Next, PCSK9 is incubated with LDLR on the plate. Finally, the plate is treated with Anti-His HRP-antibody followed by addition of an HRP substrate to produce chemiluminescence, measured using a chemiluminescence reader.
Figure 1: Illustration of the ELISA-based PCSK9(His)-LDLR Binding Assay Kit.
Need us to run inhibitor screens or profile your compounds against PCSK9(His)-LDLR? Check out our PCSK9 Screening Services.
- PBS (Phosphate Buffer Saline)
- Luminometer or microplate reader capable of reading chemiluminescence
- Rotating or rocker platform
Catalog # | Name | Amount | Storage |
71204 | PCSK9(His)* | 10 µg | -80°C |
71205 | LDLR* | 10 µg | -80°C |
Anti-His HRP-D Antibody-D | 10 µl | -80°C | |
33298 | 3x PL-01 Assay Buffer | 50 ml | -20°C |
79727 | 3x PL-02 Assay Buffer | 50 ml | -20°C |
79728 | Blocking Buffer 2 | 50 ml | +4°C |
79670 | ELISA ECL Substrate A (translucent bottle) | 6 ml | Room Temp |
ELISA ECL Substrate B (brown bottle) | 6 ml | Room Temp | |
79699 | White 96-well microplate | 1 | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
PCSK9 (Proprotein convertase subtilisin/kexin type 9) functions as a negative regulator of hepatic low-density lipoprotein receptors (LDLRs) and therefore is a critical regulator of cholesterol metabolism. It is an endopeptidase that binds to the EGFR-like ectodomain of LDLR, leading to LDLR degradation, which in turn, results in increased circulating LDL. Inhibiting the PCSK9-LDLR interaction is an increasingly desirable therapeutic approach for lowering LDL-cholesterol levels to replace or supplement statins. New therapies are critical for addressing atherosclerosis, stroke, heart disease, and other cardiovascular disorders.